Pulmonary Fibrosis Treatment Market

Global Market Study on Pulmonary Fibrosis Treatment: Monotherapy to Account for Bulk of Market Share

Pulmonary Fibrosis Treatment Market Segmented By Monotherapy, Combination Therapy with Idiopathic Pulmonary Fibrosis (IPF), Familial PF Indication

  • May-2021
  • PMRREP30070
  • 277 Pages
  • Healthcare

About the Report

North America is the leading revenue contributor to the global market for pulmonary fibrosis treatment. This is due to continuous development of innovative products by leading and emerging vendors in developed countries such as the U.S. and Canada. Pulmonary fibrosis causes shortness of breath initially, and with worsening lung condition, it makes breathing difficult without supportive care such as oxygen therapy or treatment drugs that slow down the progression of the disease.

Besides, idiopathic pulmonary fibrosis (IPF) is a progressive (non-reversible) disease that results in lung scarring, altering the lung’s normal functioning. The common signs and symptoms of pulmonary fibrosis are shortness of breath (i.e. dyspnea) and a stubborn nonproductive cough.

Incidence of IPF is rising and the disease is estimated to affect 3 million people globally (13 to 20 per 100,000 people). Considering the current pandemic scenario, global burden of fibrotic lung disease is expected to rise largely as a result of SARS-CoV-2/COVID-19. This can be primarily attributed to long-term exposure of patients to mechanical ventilation. 81% patients are aged more than 40 years with pulmonary fibrosis, as per the Pulmonary Fibrosis Foundation.

In its latest revised study, ESOMAR-certified market research and consulting firm Persistence Market Research offers insights about key factors driving demand for pulmonary fibrosis treatment. The report tracks the market in 20+ high-growth countries, along with analyzing the impact COVID-19 has had on the market overall.

Find Out More about the Report Coverage


  • F. Hoffman - La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd (Cipla)
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • FibroGen Inc.
  • Galecto Inc

Future Outlook for Pulmonary Fibrosis Treatment Looks Brighter in Comparison to Historic Growth

Exact causes for the development of pulmonary fibrosis are still unknown. Idiopathic pulmonary fibrosis, makes up for around 85% to 90% of all pulmonary fibrosis cases. Research activities to find out the cause and possible breakthrough therapy for the effective treatment of pulmonary fibrosis are going on extensively in the Western world. Various universities, and pharmaceutical & biopharmaceutical companies are trying to innovate novel treatment pathways for pulmonary fibrosis.

For instance, in 2019, The Pulmonary Fibrosis Foundation (PFF) announced the launch of PRECISIONS, a research aimed to support precision medicine for IPF. This new technology will enable scientists to isolate and examine specific genetic and molecular levels, thus creating novel therapies for IPF patients. This ongoing research study has received a grant of US$ 22 million from the National Institute of the Health (NIH) and Three Lake Partners, a philanthropic family organization

Increasing innovation in the field of pulmonary fibrosis and great acceptance of such innovations by patients will aid market expansion. This will create opportunities for the expansion of the pulmonary fibrosis treatment market size over the forecast period, which is projected to increase at a CAGR of over 6% through 2031.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

What is the Impact of Orphan Drugson Pulmonary Fibrosis Treatment?

FDA orphan drug designation programs offer a unique status to biologics and drugs intended to treat, diagnose, and prevent diseases in the U.S. The FDA orphan drug designation offers an exclusivity period of seven-year marketing for competition and certain incentives, including tax credits, federal grants, and a waiver of PDUFA filing fees.

For example, in August 2019, Daewoong Pharmaceutical received orphan drug designation from UFDA for its DWN 12088, oral IPF therapy.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

How Will Rising Prevalence of IPF Aid Market Growth?

The number of people smoking is increasing at a rapid pace across the world. As per the World Health Organization (WHO), in 2018, more than 1 billion people smoked tobacco around the world. Smoking is linked to higher chances of developing pulmonary fibrosis, and is also responsible for worsening of the disease. The probability of developing pulmonary fibrosis is higher in smokers or ex-smokers as compared to persons who never smoked.

For instance, as per the Centers for Disease Control and Prevention, more than 14% (~34.5 million) adults in the U.S. smoked tobacco as of 2019, and more than 6.9 million adults smoked tobacco in the U.K. These factors are often considered responsible for increase in morbidity and mortality due to pulmonary diseases.


Explore Persistence Market Research’s expertise in promulgation of the business !

Will Diagnostic Issues of Pulmonary Fibrosis Limit Market Growth?

The cause of pulmonary fibrosis is unknown, which makes the diagnosis of the disease tougher. A majority of pulmonary fibrosis diagnoses are mistaken for Chronic Obstructive Pulmonary Disease (COPD), leading to delayed diagnosis and worsened stage of the disease. Delayed diagnosis makes the management of pulmonary fibrosis difficult as well as increases cost. Lack of standard guidelines further make diagnosis difficult.

For instance, as per the Department of Respiratory Medicine, Herlev and Gentofte Hospital, Kildegardsvej, more than 41% of pulmonary fibrosis cases are misdiagnosed. A series of tests are required to diagnose pulmonary fibrosis, such as Pulmonary Function Tests (PFTs) or Lung Function Tests, six-minute walk test, and Aahigh-resolution CT scan (HRCT). Even with these tests, diagnosis is not confirmed, and biopsy is also carried out often.

Country-wise Insights

How are Technological Innovations Creating Scope for Expansion in the U.S.?

Technological innovations in pulmonary fibrosis treatment have amplified the scope of innovative medication in the field of pulmonary fibrosis. Technological advancements play a very important role in the U.S. market. Apart from traditional off-label corticosteroid treatment options, drugs such as Offer (nintedanib) by Boehringer Ingelheim Pharmaceuticals, Inc. and Esbriet (Pirfenidone) by Genentech Inc. received marketing approval in 2014, changing the dynamics of the market in the country.

Why Is Demand for Pulmonary Fibrosis Treatment Surging across the U.K?

Rising old population is being seen in developed countries such as the U.K. and the age group above 60 is more prone to pulmonary disorders. Large number of old patients are hospitalized due to respiratory problems, mostly in Western European countries. Moreover, market players are entering into collaborations with leading organizations such as the National Institutes of Health to gain significant clinical evidence for their products.

How are Market Consolidation Activities Influencing the Market in Japan?

Per capita spending on healthcare is increasing, globally. People’s desire and ability to spend on wellness has led to an incremental shift in pharmaceutical expenditure. Also, global per capita healthcare spending has almost doubled over the past few years, especially in countries such as Japan.

Rapid economic growth and growing disposable income are factors that can be attributed to the growth of overall healthcare industry. Increasing pharmaceutical spending is expected to result in rising demand for advanced drugs/therapies for pulmonary fibrosis, which, in turn, will create high growth opportunities for market players over the forecast period.

Why are Middle-income Countries Such as India Showing Positive Growth?

It has been observed that the middle-income population is having less awareness regarding pulmonary fibrosis and as such the disease is diagnosed late and the severity is increased. Prevalence of smoking has increasing in developed as well as developing countries.

As per WHO, prevalence of smoking is higher in countries with upper-middle income as compared to high-income countries. This creates a better opportunities for pharma players to increase their revenues from developing countries such as India.

Category Insights

Why is Monotherapy Witnessing High Demand?

Monotherapy is a single drug that is given at one time, and has less side effects on the body. Single therapy medicines are more accepted by patients across the world. As such, this segment is expected to flourish and expand at a CAGR of over 6% through 2031.

Will Increasing Prevalence of IPF Shape Market Expansion?

Incidence of IPF is rising, and the disease is estimated to affect 3 million people, globally. However, there is no accurate statistics reported for the exact incidence and prevalence rate. Significant prevalence of idiopathic pulmonary disorder is observed in the United States, Europe, and the Middle East as compared to the Asian continent.

In the U.S. approximately 100,000 people are affected, with an annual incidence of 30, 0000 to 40,000 cases. In Europe, the highest rate of IPF is observed in the U.K., with incidence rates between 4.6-8.5 per 100,000 per year and 6,000 people diagnosed annually. On the other hand, major Asian economies (South Korea, Taiwan, and Japan) report the lowest rate of IPF globally, with incidence of 1.2 to 4.16 per 100,000 people.

Competitive Landscape

Some of the leading companies operating in the market are:

  • F. Hoffman - La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd (Cipla)
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • FibroGen Inc.
  • Galecto Inc

Scope of the Report



Forecast Period


Historical Data Available for


Market Analysis

USD billion for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • Turkey
  • South Africa

Key Segments Covered

  • Therapy
  • Indication
  • Distribution Channel
  • Region

Key Companies Profiled

  • F. Hoffman - La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd (Cipla)
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • FibroGen Inc.
  • Galecto Inc

Report Coverage

  • Market Forecasts
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Market Segmentation by Category


  • Monotherapy
  • Combination Therapy


  • Idiopathic Pulmonary Fibrosis (IPF)
  • Familial PF
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies


  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Key Questions Answered in Report

  • Which is the most lucrative market for pulmonary fibrosis treatment?

    The U.S. currently leads the global market for pulmonary fibrosis treatment.

  • Which is the most used type of therapy?

    Monotherapy is dominating the market in terms of therapy. Due to its single drug use and cost effectiveness, the segment will continue rising through the forecast period.

  • Which distribution channel is driving revenue of market players?

    Hospitals pharmacies are the leading service providers in the market for pulmonary fibrosis treatment, owing to their advanced medical facilities and higher footfall of patients.


Elder Care Products Market

Elder Care Products Market projected to expand at a healthy 5.4% CAGR, global industry valuation is set to reach US$ 38.61 Bn by the end of 2032..

Medical Marijuana Market

The global medical marijuana market is anticipated to surge to US$ 76.5 Bn by 2031, reflecting a CAGR of 14.8% over the forecast period (2021-2031)..

Biologics Contract Manufacturing Demand

PMR’s study on biologics contract manufacturing demand offers information divided into five important segments— product, platform, application, therapeutic area & regional outlook.

Active Pharmaceutical Ingredient Market

Global active pharmaceutical ingredient market is predicted to expand at a CAGR of more than 4% over the forecast period (2021–2031)..

Our Clients

Our Clients